Home Blog of Signal Transduction Others PARP Resvertrol targets a human tRNA synthetase for activation of NAD+-dependent PARP1

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Resvertrol targets a human tRNA synthetase for activation of NAD+-dependent PARP1

 

Resveratrol (RSV) is well known for its effect of lifespan extension and against serious diseases such as diabetic and cancer. Previous studies showed it enable to induce survival genes by starting a stress response. Mathew Sajish and Paul Schimmel found RSV interacts with tyrosyl transfer-RNA (tRNA) synthetase (TyrRS), which translocates to the nucleus in response to stress, to initiating its effect in nuclear. The letter was published online in Nature.

 

Researchers found RSV strongly inhibits TyrRS by binding to its active site with a co-crystal structure. The interaction nullifies the catalytic activity of TyrRS, consequently mediates TyrRS to stimulate NAD+-dependent auto-poly-ADP-ribosylation of poly polymerase 1 (PARP1), a main regulator of NAD+ metabolism and associated signaling. The TyrRS-PARP1-NAD+ collaboration can be blocked by RSV after replacing tyrosyl adenylate analogue by RSV in vivo. Moreover, a short interfering RNA (siRNA), that interfered PARP1 activities, significantly reduce the expression level of RSV-targeted genes encoding Hsp72, p-AMPK, SIR1, FOXO3A, etc. The findings indicate a critical role of TyrRS in PARP1 induced-stress response activated by RSV.

 

Reference:
Nature. 2014 Dec 22.10.1038/nature14028. 

Related Products

Cat.No. Product Name Information
S2178 AG-14361 AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Related Targets

PARP Others